Skip to content

Oncotelic Therapeutics, Inc.: 10-Q filed 2025-11-17

What Oncotelic Therapeutics, Inc. reported in its quarterly report filed 2025-11-17 (fiscal Q3 2025): 24 published measures, 74 facts as tagged in accession 0001493152-25-023834.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-17
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-023834 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Oncotelic Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3028,156,163USD
At 2024-12-3126,677,426USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3020,079,663USD
At 2024-12-3119,199,914USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-309,050,578USD
At 2024-12-318,251,631USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-30409,000USD
At 2024-12-3186,128USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,047,365USD92
2025-01-01 to 2025-09-30-1,068,225USD273
2024-07-01 to 2024-09-30-3,304,486USD92
2024-01-01 to 2024-09-30-3,922,998USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-600,128USD273
2024-01-01 to 2024-09-30-636,387USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30923,000USD273
2024-01-01 to 2024-09-30615,000USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-39,108,893USD
At 2024-12-31-38,040,668USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-30426,435,213shares92
2025-01-01 to 2025-09-30414,315,703shares273
2024-07-01 to 2024-09-30407,289,888shares92
2024-01-01 to 2024-09-30403,428,494shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-300USD/shares273
2024-07-01 to 2024-09-30-0.01USD/shares92
2024-01-01 to 2024-09-300USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-30183,742USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-490,973USD92
2025-01-01 to 2025-09-30-658,039USD273
2024-07-01 to 2024-09-30-3,280,757USD92
2024-01-01 to 2024-09-30-3,544,559USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-301,612,948USD
At 2024-12-31134,211USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3020,079,663USD
At 2024-12-3119,199,914USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2025-09-302,788,230USD
At 2024-12-312,788,230USD
At 2023-12-315,988,230USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-303,976USD
At 2024-12-3118,976USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30490,973USD92
2025-01-01 to 2025-09-30658,039USD273
2024-07-01 to 2024-09-303,280,757USD92
2024-01-01 to 2024-09-303,544,559USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-30439,446,318shares
At 2024-12-31407,289,618shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3043,765,008USD
At 2024-12-3142,219,400USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2025-09-308,076,500USD
At 2025-06-307,393,895USD
At 2025-03-317,183,446USD
At 2024-12-317,477,512USD
At 2024-09-308,131,972USD
At 2024-06-3011,503,623USD
At 2024-03-3111,249,391USD
At 2023-12-3111,611,537USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,114,369USD92
2025-01-01 to 2025-09-30-1,268,184USD273
2025-04-01 to 2025-06-30210,449USD91
2025-01-01 to 2025-03-31-364,264USD90
2024-07-01 to 2024-09-30-3,371,651USD92
2024-01-01 to 2024-09-30-4,124,998USD274
2024-04-01 to 2024-06-30-278,173USD91
2024-01-01 to 2024-03-31-475,175USD91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30490,547USD92
2025-01-01 to 2025-09-30657,019USD273
2024-07-01 to 2024-09-3080,277USD92
2024-01-01 to 2024-09-30343,347USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-623,396USD92
2025-01-01 to 2025-09-30-610,145USD273
2024-07-01 to 2024-09-30-90,894USD92
2024-01-01 to 2024-09-30-580,439USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-30285,260USD273
2024-01-01 to 2024-09-30281,260USD274

Inspect the source

Entity
Oncotelic Therapeutics, Inc. / CIK 0000908259
Captured
2026-09-20T05:05:47.535Z
SEC response SHA-256
6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))